20,000 Shares in Royalty Pharma plc (NASDAQ:RPRX) Purchased by Raiffeisen Bank International AG

Raiffeisen Bank International AG acquired a new stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 20,000 shares of the biopharmaceutical company's stock, valued at approximately $506,000.

Several other large investors also recently bought and sold shares of the business. Nissay Asset Management Corp Japan ADV lifted its stake in shares of Royalty Pharma by 0.7% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock worth $1,238,000 after purchasing an additional 349 shares during the period. Keene & Associates Inc. raised its position in Royalty Pharma by 1.9% in the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock worth $495,000 after acquiring an additional 370 shares during the period. National Bank of Canada FI boosted its stake in shares of Royalty Pharma by 21.8% during the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 371 shares during the last quarter. Blue Trust Inc. grew its stake in shares of Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 376 shares during the period. Finally, Sanctuary Advisors LLC increased its holdings in Royalty Pharma by 0.9% in the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock worth $1,068,000 after acquiring an additional 388 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Price Performance

Shares of RPRX stock traded down $1.16 during mid-day trading on Tuesday, hitting $33.09. The company had a trading volume of 7,445,404 shares, compared to its average volume of 3,458,649. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock's 50 day moving average price is $32.43 and its 200-day moving average price is $30.08. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.50. The company has a market capitalization of $19.07 billion, a P/E ratio of 22.82, a P/E/G ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.99 by $0.07. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. The business had revenue of $839.00 million for the quarter, compared to analysts' expectations of $724.69 million. Equities research analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.66%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio (DPR) is presently 47.57%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on RPRX. Morgan Stanley assumed coverage on shares of Royalty Pharma in a research report on Friday. They issued an "overweight" rating and a $51.00 price target for the company. StockNews.com downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a report on Tuesday. Finally, Citigroup reissued a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.